{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:32:59Z","timestamp":1781764379737,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST104-2321-B-002-058"],"award-info":[{"award-number":["MOST104-2321-B-002-058"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW105-CDC-C-114-00103"],"award-info":[{"award-number":["MOHW105-CDC-C-114-00103"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4292-y","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T10:39:03Z","timestamp":1524134343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-7615","authenticated-orcid":false,"given":"Cheng-Maw","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Fu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rey-Heng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Huang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"4292_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"4292_CR2","doi-asserted-by":"publisher","first-page":"45846","DOI":"10.1038\/srep45846","volume":"7","author":"MCS Wong","year":"2017","unstructured":"Wong MCS, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;7:45846.","journal-title":"Sci Rep"},{"key":"4292_CR3","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"MH Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N Engl J Med. 1997;336:1855\u20139.","journal-title":"N Engl J Med"},{"key":"4292_CR4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/hep.26703","volume":"59","author":"YP Yeh","year":"2014","unstructured":"Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014;59:1840\u20139.","journal-title":"Hepatology"},{"key":"4292_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/apt.13891","volume":"45","author":"D Patel","year":"2017","unstructured":"Patel D. Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century. Aliment Pharmacol Ther. 2017;45:561\u20132.","journal-title":"Aliment Pharmacol Ther"},{"key":"4292_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745\u201359.","journal-title":"Nat Rev Cancer"},{"key":"4292_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jch.12225","volume":"16","author":"SJ Mann","year":"2014","unstructured":"Mann SJ, Christos PJ. ACE inhibitors and ARBs: do they reduce the risk of cancer? J Clin Hypertens (Greenwich). 2014;16:6\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"4292_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jch.12228","volume":"16","author":"YY Chiang","year":"2014","unstructured":"Chiang YY, Chen KB, Tsai TH, Tsai WC. Lowered cancer risk with ACE inhibitors\/ARBs: a population-based cohort study. J Clin Hypertens (Greenwich). 2014;16:27\u201333.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"4292_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"4292_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00535-012-0651-7","volume":"48","author":"Y Tamaki","year":"2013","unstructured":"Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491\u2013503.","journal-title":"J Gastroenterol"},{"key":"4292_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00535-013-0906-y","volume":"49","author":"H Yoshiji","year":"2014","unstructured":"Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, et al. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol. 2014;49:1421\u20139.","journal-title":"J Gastroenterol"},{"key":"4292_CR12","first-page":"3335","volume":"25","author":"H Yoshiji","year":"2005","unstructured":"Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res. 2005;25:3335\u201340.","journal-title":"Anticancer Res"},{"key":"4292_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1111\/jgh.12988","volume":"30","author":"A Facciorusso","year":"2015","unstructured":"Facciorusso A, Del Prete V, Crucinio N, Muscatiello N, Carr BI, Di Leo A, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol. 2015;30:1643\u201350.","journal-title":"J Gastroenterol Hepatol"},{"key":"4292_CR14","first-page":"1547","volume":"26","author":"H Yoshiji","year":"2011","unstructured":"Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, et al. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep. 2011;26:1547\u201353.","journal-title":"Oncol Rep"},{"key":"4292_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2009.04.011","volume":"51","author":"H Yoshiji","year":"2009","unstructured":"Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 2009;51:315\u201321.","journal-title":"J Hepatol"},{"key":"4292_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"CY Wu","year":"2012","unstructured":"Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906\u201314.","journal-title":"JAMA"},{"key":"4292_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329\u201337.","journal-title":"Ann Intern Med"},{"key":"4292_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrgastro.2013.143","volume":"11","author":"S Singh","year":"2014","unstructured":"Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45\u201354.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4292_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cld.568","volume":"8","author":"J Choi","year":"2016","unstructured":"Choi J, Roberts LR. Statins and metformin for chemoprevention of hepatocellular carcinoma. Clin Liver Dis. 2016;8:48\u201352.","journal-title":"Clin Liver Dis"},{"key":"4292_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ajg.2013.5","volume":"108","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881\u201391.","journal-title":"Am J Gastroenterol"},{"key":"4292_CR21","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","volume":"31","author":"YT Tsan","year":"2013","unstructured":"Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31:1514\u201321.","journal-title":"J Clin Oncol"},{"key":"4292_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.2011.36.0917","volume":"30","author":"YT Tsan","year":"2012","unstructured":"Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623\u201330.","journal-title":"J Clin Oncol"},{"key":"4292_CR23","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1940-6207.CAPR-15-0126","volume":"8","author":"JL Petrick","year":"2015","unstructured":"Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev Res (Phila). 2015;8:1156\u201362.","journal-title":"Cancer Prev Res (Phila)"},{"key":"4292_CR24","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/jnci\/djs452","volume":"104","author":"VV Sahasrabuddhe","year":"2012","unstructured":"Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"4292_CR25","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","volume":"35","author":"S Suissa","year":"2012","unstructured":"Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35:2665\u201373.","journal-title":"Diabetes Care"},{"key":"4292_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canep.2016.06.009","volume":"43","author":"B Yang","year":"2016","unstructured":"Yang B, Petrick JL, Chen J, Hagberg KW, Sahasrabuddhe VV, Graubard BI, et al. Associations of NSAID and paracetamol use with risk of primary liver cancer in the clinical practice research datalink. Cancer Epidemiol. 2016;43:105\u201311.","journal-title":"Cancer Epidemiol"},{"key":"4292_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2012.249","volume":"9","author":"B Sev\u00e1 Pess\u00f4a","year":"2013","unstructured":"Sev\u00e1 Pess\u00f4a B, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AH. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 2013;9:26\u201336.","journal-title":"Nat Rev Nephrol"},{"key":"4292_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/CS20120461","volume":"124","author":"DG Passos-Silva","year":"2013","unstructured":"Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond). 2013;124:443\u201356.","journal-title":"Clin Sci (Lond)"},{"key":"4292_CR29","doi-asserted-by":"publisher","first-page":"147032031662871","DOI":"10.1177\/1470320316628717","volume":"17","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Li N, Li F, Zhou Z, Han Q, Lv Y, et al. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J Renin-Angiotensin-Aldosterone Syst. 2016;17:1470320316628717.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"4292_CR30","first-page":"539","volume":"5","author":"H Yoshiji","year":"2012","unstructured":"Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Douhara A, et al. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. Mol Med Rep. 2012;5:539\u201344.","journal-title":"Mol Med Rep"},{"key":"4292_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/aje\/kwq211","volume":"172","author":"MJ Khoury","year":"2010","unstructured":"Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol. 2010;172:517\u201324.","journal-title":"Am J Epidemiol"},{"key":"4292_CR32","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.24197","volume":"53","author":"CY Dai","year":"2011","unstructured":"Dai CY, Yeh ML, Huang JF, Chuang WL, Yu ML. Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. Hepatology. 2011;53:1399.","journal-title":"Hepatology"},{"key":"4292_CR33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/MLR.0b013e3182a502ba","volume":"51","author":"CH Chang","year":"2013","unstructured":"Chang CH, Lin JW, Wu LC, Liu CH, Lai MS. National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report. Med Care. 2013;51:908\u201313.","journal-title":"Med Care"},{"key":"4292_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037978","volume":"7","author":"CH Lee","year":"2012","unstructured":"Lee CH, Lee MC, Lin HH, Shu CC, Wang JY, Lee LN, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One. 2012;7:e37978.","journal-title":"PLoS One"},{"key":"4292_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","volume":"57","author":"CY Peng","year":"2012","unstructured":"Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442\u201350.","journal-title":"J Hepatol"},{"key":"4292_CR36","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/ajg.2016.330","volume":"111","author":"JD Yang","year":"2016","unstructured":"Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis. Am J Gastroenterol. 2016;111:1573\u201380.","journal-title":"Am J Gastroenterol"},{"key":"4292_CR37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-015-0401-2","volume":"75","author":"A Majumdar","year":"2015","unstructured":"Majumdar A, Kitson MT, Roberts SK. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. Drugs. 2015;75:823\u201334.","journal-title":"Drugs"},{"key":"4292_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245\u201355.","journal-title":"Lancet"},{"key":"4292_CR39","first-page":"227","volume":"31","author":"E Fransvea","year":"2009","unstructured":"Fransvea E, Paradiso A, Antonaci S, Giannelli G. HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol. 2009;31:227\u201333.","journal-title":"Cell Oncol"},{"key":"4292_CR40","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-14-0122","volume":"21","author":"J Friemel","year":"2015","unstructured":"Friemel J, Rechsteiner M, Frick L, B\u00f6hm F, Struckmann K, Egger M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015;21:1951\u201361.","journal-title":"Clin Cancer Res"},{"key":"4292_CR41","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-08-2484","volume":"69","author":"F Vincent","year":"2009","unstructured":"Vincent F, Bonnin P, Clemessy M, Contrer\u00e8s JO, Lamand\u00e9 N, Gasc JM, et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 2009;69:2853\u201360.","journal-title":"Cancer Res"},{"key":"4292_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.07.009","volume":"20","author":"E Shirvani-Dastgerdi","year":"2016","unstructured":"Shirvani-Dastgerdi E, Schwartz RE, Ploss A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol. 2016;20:1\u201310.","journal-title":"Curr Opin Virol"},{"key":"4292_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2015.02.030","volume":"459","author":"G Ye","year":"2015","unstructured":"Ye G, Qin Y, Lu X, Xu X, Xu S, Wu C, et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun. 2015;459:18\u201323.","journal-title":"Biochem Biophys Res Commun"},{"key":"4292_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.surg.2011.12.015","volume":"151","author":"CM Ho","year":"2012","unstructured":"Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012;151:700\u20139.","journal-title":"Surgery"},{"key":"4292_CR45","unstructured":"Drugs & Diseases: everolimus (Rx), \n                    Medscape.com\n                    \n                   \n                    http:\/\/reference.medscape.com\/drug\/afinitor-zortress-everolimus-999101\n                    \n                  , Accessed 30 May 2017."},{"key":"4292_CR46","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","volume":"175","author":"CC Lee","year":"2015","unstructured":"Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839\u201347.","journal-title":"JAMA Intern Med"},{"key":"4292_CR47","unstructured":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm511530.htm\n                    \n                  . Accessed 20 May 2017."},{"key":"4292_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","volume":"129","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"4292_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ. 2012;344:e2697.","journal-title":"BMJ"},{"key":"4292_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","volume":"60","author":"J Dyson","year":"2014","unstructured":"Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110\u20137.","journal-title":"J Hepatol"},{"key":"4292_CR51","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.2147\/OTT.S113832","volume":"9","author":"K Bai","year":"2016","unstructured":"Bai K, Cai Q, Jiang Y, Lv L. Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies. Onco Targets Ther. 2016;9:4369\u201375.","journal-title":"Onco Targets Ther"},{"key":"4292_CR52","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/ijms16036124","volume":"16","author":"M Shimizu","year":"2015","unstructured":"Shimizu M, Shirakami Y, Sakai H, Kubota M, Kochi T, Ideta T, et al. Chemopreventive potential of green tea catechins in hepatocellular carcinoma. Int J Mol Sci. 2015;16:6124\u201339.","journal-title":"Int J Mol Sci"},{"key":"4292_CR53","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/liv.13466","volume":"37","author":"P Kolly","year":"2017","unstructured":"Kolly P, Kn\u00f6pfli M, Dufour JF. Effect of smoking on survival of patients with hepatocellular carcinoma. Liver Int. 2017;37:1682\u20137.","journal-title":"Liver Int"},{"key":"4292_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MC Cheung","year":"2016","unstructured":"Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741\u20137.","journal-title":"J Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4292-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:19:06Z","timestamp":1554837546000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4292"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4292-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"23 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of National Taiwan University Hospital, Taipei, Taiwan, approved this study (NTUH REC: 201601007\u00a0W). This retrospective study used an encrypted database; therefore, the need for informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for submission, and agree with submission to this esteemed journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have completed the Unified Competing Interest form at  (available upon request from the corresponding author) and declare that (1) no support was received from any company for the submitted work; (2) none of the authors have any relationships with any company that may have an interest in the submitted study in the last 3\u00a0years; (3) the spouses, partners, or children of the authors have no financial relationships that may be relevant to the submitted study; and (4) no author has nonfinancial interests that may be relevant to the submitted study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"401"}}